Clinical Communication
Successful rapid tocilizumab desensitization in a patient with Still disease

https://doi.org/10.1016/j.jaip.2014.04.015Get rights and content

References (7)

  • M.C. Castells et al.

    Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases

    J Allergy Clin Immunol

    (2008)
  • S. Yokota et al.

    Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan

    J Rheumatol

    (2014)
  • L. Cox et al.

    Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System

    J Allergy Clin Immunol

    (2010)
There are more references available in the full text version of this article.

Cited by (20)

  • Anaphylaxis to Drugs, Biological Agents, and Vaccines

    2022, Immunology and Allergy Clinics of North America
    Citation Excerpt :

    For patients in whom an IgE-mediated reaction is suspected, desensitization can be performed. 116Immediate HSRs related to other commonly prescribed biologics are summarized in Table 5.73,98,117–121 The risk of anaphylaxis after any vaccine is rare: 1.31 per million vaccine doses.122

  • Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs

    2020, Journal of Allergy and Clinical Immunology: In Practice
    Citation Excerpt :

    It is used to treat rheumatoid arthritis and systemic or polyarticular juvenile arthritis.501 Immediate hypersensitivity reactions to tocilizumab are rare, but several cases of anaphylaxis have been reported occurring from the second exposure onward.502,503 Skin testing (Table LVIII) is usually useful in identifying patients with an IgE-mediated hypersensitivity reaction, and desensitization (Table LIX) should be considered the method of choice to reexpose those patients to tocilizumab (Figure 6).470,474,502,503

  • Monoclonal Antibodies Hypersensitivity: Prevalence and Management

    2017, Immunology and Allergy Clinics of North America
View all citing articles on Scopus

No funding was received for this work.

Conflicts of interest: The authors declare that they have no relevant conflicts of interest.

View full text